Roche files vismodegib in the EU
This article was originally published in Scrip
Executive Summary
Roche has filed for centralised EU approval of vismodegib, a first-in-class investigational anticancer, for the treatment of adults with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.